With a new investment commitment of $5.3 billion, Eli Lilly plans to more than double its investment in the Lebanon production site in the US state of Indiana. This expansion is intended to significantly increase production capacity for active pharmaceutical ingredients (API) for two drugs currently in high demand for the treatment of obesity and type 2 diabetes. At a total of nine billion dollars...